ATE411036T1 - Verwendung von aplidine in der behandlung von pankreaskrebs - Google Patents

Verwendung von aplidine in der behandlung von pankreaskrebs

Info

Publication number: ATE411036T1
Authority: AT; Austria
Prior art keywords: aplidine; treatment; pancreas cancer; cancer; pancreas
Prior art date: 2001-10-19

Application number

AT02770106T

Other languages

English (en)

Inventor

R Mangues

R Henriquez

J Jimeno

Original Assignee

Pharma Mar Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-19

Filing date

2002-10-21

Publication date

2008-10-15

2002-04-15 Priority claimed from GB0208624A external-priority patent/GB0208624D0/en

2002-10-21 Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa

2008-10-15 Application granted granted Critical

2008-10-15 Publication of ATE411036T1 publication Critical patent/ATE411036T1/de

Links

206010061902 Pancreatic neoplasm Diseases 0.000 title abstract 3
208000015486 malignant pancreatic neoplasm Diseases 0.000 title abstract 2
208000008443 pancreatic carcinoma Diseases 0.000 title abstract 2
UUSZLLQJYRSZIS-LXNNNBEUSA-N plitidepsin Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)C(C)=O UUSZLLQJYRSZIS-LXNNNBEUSA-N 0.000 title abstract 2
229950008499 plitidepsin Drugs 0.000 title abstract 2
108010049948 plitidepsin Proteins 0.000 title abstract 2
230000001394 metastastic effect Effects 0.000 abstract 1
206010061289 metastatic neoplasm Diseases 0.000 abstract 1
201000002528 pancreatic cancer Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT02770106T 2001-10-19 2002-10-21 Verwendung von aplidine in der behandlung von pankreaskrebs ATE411036T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US34841201P	2001-10-19	2001-10-19
GB0208624A GB0208624D0 (en)	2002-04-15	2002-04-15	Use of aplidine for the treatment of pancreatic cancer

Publications (1)

Publication Number	Publication Date
ATE411036T1 true ATE411036T1 (de)	2008-10-15

Family

ID=26247033

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02770106T ATE411036T1 (de)	2001-10-19	2002-10-21	Verwendung von aplidine in der behandlung von pankreaskrebs

Country Status (9)

Country	Link
US (2)	US20050004012A1 (de)
EP (1)	EP1435991B1 (de)
AT (1)	ATE411036T1 (de)
AU (1)	AU2002336206B2 (de)
CA (1)	CA2462642A1 (de)
DE (1)	DE60229414D1 (de)
ES (1)	ES2315404T3 (de)
PT (1)	PT1435991E (de)
WO (1)	WO2003033013A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9803448D0 (en)	1998-02-18	1998-04-15	Pharma Mar Sa	Pharmaceutical formulation
KR100518986B1 (ko) *	1999-11-15	2005-10-06	파르마 마르, 에스.에이.	아플리딘을 사용하여 암을 치료하는 방법
UA76718C2 (uk)	2000-06-30	2006-09-15	Фарма Мар, С.А.	Протипухлинні похідні аплідину
HK1054191A1 (zh)	2000-10-12	2003-11-21	Pharma Mar, S.A.	施用aplidine時同時使用myoprotector的癌症治療
RU2341283C2 (ru) *	2003-03-12	2008-12-20	Фарма Мар, С.А.	Усовершенствованное лечение опухолей
ATE406171T1 (de)	2003-03-12	2008-09-15	Dana Farber Cancer Inst Inc	Aplidine zur behandlung von multiplem myelom
US8258098B2 (en) *	2006-02-28	2012-09-04	Pharma Mar, S.A.	Antitumoral treatments
WO2008080956A1 (en) *	2006-12-29	2008-07-10	Pharma Mar, S.A.	Prognostic molecular markers for the cancer therapy with aplidine
JP2011500650A (ja) *	2007-10-19	2011-01-06	ファルマ・マール・ソシエダード・アノニマ	改良された抗腫瘍治療
AU2009221720A1 (en) *	2008-03-07	2009-09-11	Pharma Mar, S.A.	Improved anticancer treatments
US11332480B2 (en)	2017-04-27	2022-05-17	Pharma Mar, S.A.	Antitumoral compounds

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4342744A (en) *	1979-07-19	1982-08-03	Lever Brothers Company	Hair treatment products
US4493796A (en) *	1980-09-12	1985-01-15	Board Of Trustees, Univ. Of Ill.	Didemnins A, B, C, and derivatives thereof, as antiviral agents
US4950649A (en) *	1980-09-12	1990-08-21	University Of Illinois	Didemnins and nordidemnins
IT1153974B (it) *	1982-09-23	1987-01-21	Erba Farmitalia	Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
GB8922026D0 (en) *	1989-09-29	1989-11-15	Pharma Mar Sa	Novel anti-viral and cytotoxic agent
FR2698543B1 (fr) *	1992-12-02	1994-12-30	Rhone Poulenc Rorer Sa	Nouvelles compositions à base de taxoides.
US5462726A (en) *	1993-12-17	1995-10-31	Bristol-Myers Squibb Company	Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
ATE220894T1 (de) *	1993-12-29	2002-08-15	Matrix Pharma	Zusammensetzung für lokale freigabe von zytostatika
US5861439A (en) *	1994-11-14	1999-01-19	Alza Corporation	Method for enhanced electrotransport agent delivery
US6365597B1 (en) *	1996-02-14	2002-04-02	Aventis Pharmaceuticals Inc.	4-aza steroids
JP4172726B2 (ja) *	1996-05-22	2008-10-29	ルイトポルド・ファーマシューティカルズ・インコーポレーテッド	シス―ドコサヘキサエン酸とドセタキセルとの共有複合体を含有する製剤
US6156724A (en) *	1996-06-07	2000-12-05	Rinehart; Kenneth L.	Uses of didemnins as immunomodulating agents
US6034058A (en) *	1997-04-15	2000-03-07	Rinehart; Kenneth L.	Semi-synthetic alanyl dilemnin analogs
EP0981352B8 (de) *	1997-05-07	2009-06-17	Pharma Mar, S.A.	Verwendung von Aplidine zur Behandlung von kardiovaskulären Erkrankungen
PT1100589E (pt) *	1998-07-30	2005-05-31	Sigma Tau Ind Farmaceuti	Utilizacao de propionil-l-carnitina e acetil-l-carnitina na preparacao de medicamentos com actividade anticancerigena
US20010021380A1 (en) *	1999-04-19	2001-09-13	Pluenneke John D.	Soluble tumor necrosis factor receptor treatment of medical disorders
US6890904B1 (en) *	1999-05-25	2005-05-10	Point Therapeutics, Inc.	Anti-tumor agents
KR100518986B1 (ko) *	1999-11-15	2005-10-06	파르마 마르, 에스.에이.	아플리딘을 사용하여 암을 치료하는 방법
US6509315B1 (en) *	2000-04-07	2003-01-21	The Trustees Of The University Of Pennsylvania	Didemnin analogs and fragments and methods of making and using them
CA2423462A1 (en) *	2000-10-05	2002-04-11	Immunex Corporation	Nectin polypeptides, polynucleotides, methods of making and use thereof
AU2002224417A1 (en) *	2000-10-18	2002-04-29	Immunex Corporation	Methods for treating il-18 mediated disorders

2002
- 2002-10-21 ES ES02770106T patent/ES2315404T3/es not_active Expired - Lifetime
- 2002-10-21 AT AT02770106T patent/ATE411036T1/de not_active IP Right Cessation
- 2002-10-21 DE DE60229414T patent/DE60229414D1/de not_active Expired - Lifetime
- 2002-10-21 US US10/492,659 patent/US20050004012A1/en not_active Abandoned
- 2002-10-21 CA CA002462642A patent/CA2462642A1/en not_active Abandoned
- 2002-10-21 WO PCT/GB2002/004816 patent/WO2003033013A1/en not_active Ceased
- 2002-10-21 EP EP02770106A patent/EP1435991B1/de not_active Expired - Lifetime
- 2002-10-21 PT PT02770106T patent/PT1435991E/pt unknown
- 2002-10-21 AU AU2002336206A patent/AU2002336206B2/en not_active Ceased
2009
- 2009-10-23 US US12/604,900 patent/US20100041594A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1435991B1 (de)	2008-10-15
ES2315404T3 (es)	2009-04-01
WO2003033013A1 (en)	2003-04-24
AU2002336206B2 (en)	2007-11-29
EP1435991A1 (de)	2004-07-14
DE60229414D1 (de)	2008-11-27
CA2462642A1 (en)	2003-04-24
US20100041594A1 (en)	2010-02-18
US20050004012A1 (en)	2005-01-06
PT1435991E (pt)	2009-01-16

Legal Events

Date	Code	Title	Description
2009-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
BR9707233A (pt)	1999-07-20	Fenantridinas
DE60111570D1 (de)	2005-07-21	Isoindolin-1-on als glukokinaseaktivatoren
DE60031248D1 (de)	2006-11-23	Elektroaktive pore
ID29070A (id)	2001-07-26	Fenilfenantridina dengan aktifitas pencegah pde-iv
DE60033658D1 (de)	2007-04-12	Behandlung von prostata-krebs mit anti-erbb2 antikörpern
ATE348616T1 (de)	2007-01-15	2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
ATE353217T1 (de)	2007-02-15	3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
DE60040981D1 (de)	2009-01-15	BEHANDLUNG MIT ANTI-ErbB2 ANTIKÖRPERN
DE60117605D1 (de)	2006-04-27	Thiazolyl-inhibitoren von tyrosinkinasen der tec-familie
TR199902751T2 (xx)	2000-02-21	Proteaz inhibit�rleri.
DK0889886T3 (da)	2003-01-20	Hidtil ukendte, i 6-stilling substituerede phenanthridiner
PT998460E (pt)	2004-07-30	Novos derivados de tetrazole
DE60108857D1 (de)	2005-03-17	Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
ATE275400T1 (de)	2004-09-15	Verwendung von melatonin zur behandlung der androgenetischen und diffusen alopezie vom weiblichen typ
DE60229414D1 (de)	2008-11-27	Verwendung von aplidine in der behandlung von pankreaskrebs
DE60033918D1 (de)	2007-04-26	Polysubstituted 6-phenylphenanthridines mit pde-iv hemmender wirkung
DE60105418D1 (de)	2004-10-14	Serinprotease-inhibitoren
ATE363531T1 (de)	2007-06-15	Claudin polypeptide
DE60019894D1 (de)	2005-06-09	Phenantrhridin-n-oxides mit pde-iv hemmender wirkung
DE59909760D1 (de)	2004-07-22	Benzonaphthyridin-n-oxide mit pde3 und pde4 inhibierender aktivität
DE60025327D1 (de)	2006-03-30	6-arylphenanthridine mit pde-iv hemmender wirkung
DK1214061T3 (da)	2004-11-01	Anvendelse af docetaxel til behandling af hepatocellulært carcinom
ATE295352T1 (de)	2005-05-15	Phenanthridine-n-oxide mit pde-iv hemmender wirkung
ATE343390T1 (de)	2006-11-15	Kalzilytische verbindungen
TR200003084T2 (tr)	2001-02-21	Paroxetine askorbat